title: Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops.
abstract: This study describes corneal permeation of gatifloxacin from solid lipid nanoparticle (SLN) through the cornea and its effect on corneal hydration level. The aqueous humor levels of gatifloxacin after single topical instillation in Gate(®) Eyedrops and positively charged SLN-C were determined. A 3.37-fold increase in the relative bioavailability was observed with the SLN-C (AUC0→∞ 2.192 μg mL(-1) h) (AUC, area under the curve) as compared to Gate(®) Eyedrops (AUC0→∞ 0.651 μg mL(-1) h). The t1/2 of drug in SLN-C exhibited a 2.34-fold higher than Gate(®) Eyedrops seem to be significantly increased (p > 0.05), Cmax of gatifloxacin from SLN-C showed 1.09-fold higher concentration as compared to Gate(®) Eyedrops. The results suggested that SLNs could enhance ocular bioavailability of gatifloxacin and prolong its residence time in the eyes. Moreover, no signs of ocular irritation were seen with the SLN formulations, indicating their relative safety compared to the marketed drops.
authors.affiliation: Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, KSA.
authors.forename: Mohd
authors.initials: M
authors.lastname: Abul Kalam
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Sultana
authors.forename: Asgar
authors.initials: A
authors.lastname: Ali
authors.forename: Mohd
authors.initials: M
authors.lastname: Aqil
authors.forename: Anil K
authors.initials: AK
authors.lastname: Mishra
authors.forename: Krishna
authors.initials: K
authors.lastname: Chuttani
authors.forename: Ibrahim A
authors.initials: IA
authors.lastname: Aljuffali
authors.forename: Aws
authors.initials: A
authors.lastname: Alshamsan
mesh_terms: D000287:Administration, Topical; D000818:Animals; D001082:Aqueous Humor / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D003315:Cornea / Q000000981:diagnostic imaging / Q000187:drug effects*; D016503:Drug Delivery Systems / Q000379:methods*; D004355:Drug Stability; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D000077734:Gatifloxacin; D006041:Goats; D066298:In Vitro Techniques; D007509:Irritants / Q000494:pharmacology; D057230:Limit of Detection; D008055:Lipids / Q000737:chemistry*; D008297:Male; D053758:Nanoparticles / Q000737:chemistry*; D009883:Ophthalmic Solutions / Q000494:pharmacology*; D010539:Permeability / Q000187:drug effects; D011817:Rabbits; D011877:Radionuclide Imaging; D013667:Technetium
chemical_list: D024841:Fluoroquinolones; D007509:Irritants; D008055:Lipids; D009883:Ophthalmic Solutions; D013667:Technetium; D000077734:Gatifloxacin